SLP Q1 2026 Earnings Summary

Overall summary: SLP delivered Q1 results in line with guidance: revenue declined modestly as software softened, while services, especially MedCom, outperformed and boosted margins. Bookings and backlog improved, and management highlighted a more constructive macro and regulatory backdrop alongside progress toward an integrated, AI-enabled cloud ecosystem. Guidance for FY26 is reaffirmed, with stronger software quarters expected in Q2–Q3, though consolidation impacts, weak Clinical Ops software, and QSP licensing lumpiness remain near-term headwinds.

Growth

• Total revenue $18.4M (-3% y/y)
• Software revenue -17% y/y (48% of total); Services revenue +16% y/y (52%)
• Discovery software +3% y/y; Development software -6% y/y; Clinical Ops software -82% y/y
• Development Services +8% y/y; Commercialization (MedCom) Services +42% y/y
• TTM: Discovery software +3%, Development software +1%, Clinical Ops software -28%; Commercialization Services +191%
• Ending services backlog +18% y/y to $20.4M; 186 services projects in quarter
• 302 commercial clients; quarterly ARPC $97k; quarterly renewal rate 88% (TTM ARPC $147k; TTM renewal 87%)

Business development

• Advancing integrated product ecosystem across GastroPlus, MonolixSuite, ADMET Predictor, QSP, and Proficiency
• S+ Cloud enables interoperability and end-to-end modeling workflows
• AI-driven services and copilots to enhance data curation, analysis, and compliant reporting
• FDA issued NAM guidance supportive of in silico methodologies
• Observed uptick in client spending and accelerated year-end services bookings
• High interest in QSP models; therapeutic model licensing primarily perpetual and expected to grow y/y (lumpy quarterly)

Financials

• Adjusted EBITDA $3.5M; adjusted EPS $0.13
• Gross margin 59% (software 84%, services 36%) vs prior 54% (software 75%, services 26%)
• Other income $0.3M vs $0.1M y/y; effective tax rate 30% vs 24% y/y
• FY26 guidance maintained: revenue $79–$82M (0–4% y/y), software mix 57–62%, adjusted EBITDA margin 26–30%, adjusted diluted EPS $1.03–$1.10
• Q2 FY26 revenue outlook $21–$22M

Capital & funding

• Cash and short-term investments $35.7M
• No debt; strong free cash flow

Operations & strategy

• Reorganized services personnel to support product development, improving services margin
• Unified operating model and continued investment in validated scientific engines, cloud, and AI
• Seasonality: largest software quarters expected in Q2 and Q3 due to renewals
• Strategic acquisitions and coordinated roadmap to accelerate delivery and interoperability

Market & outlook

• Macro stabilizing: MFN pricing agreements progressing, tariff threats subsided, biotech funding improving
• Regulatory tailwind from FDA NAM guidance supporting in silico approaches
• Services strength and bookings viewed as leading indicator; software growth expected to follow
• MedCom pipeline/backlog strong; software/services mix expected to align with 57–62% software guidance
• Management reiterates FY26 guidance; expects stronger software quarters in Q2–Q3

Risks & headwinds

• Software renewal rates affected by market conditions and client consolidations/bankruptcies
• Clinical Ops (Proficiency) software materially lower, creating tough first-half comps
• QSP perpetual license timing causes revenue lumpiness and quarterly volatility
• Higher effective tax rate
• Management notes cautious stance on sustained budget recovery despite recent improvement

Sentiment: mixed